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Abstract 
 
Background—Combining two signals of cardiomyocyte injury, cardiac troponin I (cTnI) and T 
(cTnT), might overcome some individual pathophysiological and analytical limitations and 
thereby increase diagnostic accuracy for acute myocardial infarction (AMI) with a single blood 
draw. We aimed to evaluate the diagnostic performance of combinations of high sensitivity (hs) 
cTnI and hs-cTnT for the early diagnosis of AMI.  
Methods—The diagnostic performance of combining hs-cTnI (Architect, Abbott) and hs-cTnT 
(Elecsys, Roche) concentrations (sum, product, ratio and a combination algorithm) obtained at 
the time of presentation was evaluated in a large multicenter diagnostic study of patients with 
suspected AMI. The optimal rule out and rule in thresholds were externally validated in a second 
large multicenter diagnostic study. The proportion of patients eligible for early rule out was 
compared with the ESC 0/1 and 0/3 hour algorithms.  
Results—Combining hs-cTnI and hs-cTnT concentrations did not consistently increase overall 
diagnostic accuracy as compared with the individual isoforms. However, the combination 
improved the proportion of patients meeting criteria for very early rule-out. With the ESC 2015 
guideline   recommended algorithms and cut-offs, the proportion meeting rule out criteria after 
the baseline blood sampling was limited (6-24%) and assay dependent. Application of optimized 
cut-off values using the sum (9 ng/L) and product (18 ng2/L2) of hs-cTnI and hs-cTnT 
concentrations led to an increase in the proportion ruled-out after a single blood draw to 34-41% 
in the original (sum: negative predictive value (NPV) 100% (95%CI: 99.5-100%); product: NPV 
100% (95%CI: 99.5-100%) and in the validation cohort (sum: NPV 99.6% (95%CI: 99.0-
99.9%); product: NPV 99.4% (95%CI: 98.8-99.8%). The use of a combination algorithm (hs-
cTnI <4 ng/L and hs-cTnT <9 ng/L) showed comparable results for rule out (40-43% ruled out; 
NPV original cohort 99.9% (95%CI: 99.2-100%); NPV validation cohort 99.5% (95%CI: 98.9-
99.8%)) and rule-in (PPV original cohort 74.4% (95%Cl 69.6-78.8%); PPV validation cohort 
84.0% (95%Cl 79.7-87.6%)).  
Conclusions—New strategies combining hs-cTnI and hs-cTnT concentrations may significantly 
increase the number of patients eligible for very early and safe rule-out, but do not seem helpful 
for the rule-in of AMI.  
Clinical Trial Registration—APACE URL: www.clinicaltrial.gov, Unique Identifier: 
NCT00470587; ADAPT URL: www.anzctr.org.au, Unique Identifier: ACTRN12611001069943 
 
Key Words: High-sensitivity cardiac troponin; combination of assays for diagnosis; acute 
myocardial infarction; early rule-out, early rule-in 
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Clinical Perspective 
 
What is new? 
• Measuring both cardiac troponin T (hs-cTnT) and cardiac troponin I (hs-cTnI) for the 
diagnosis of acute myocardial infarction does not consistently increase overall diagnostic 
accuracy as compared with measurement of the individual troponins. 
• Using a combination of cardiac troponin T and cardiac troponin I concentrations, both 
obtained at a single blood draw at presentation, leads to a substantial increase in the 
proportion of patients in whom an acute myocardial infarction can be safely excluded. 
• In contrast, the combination of cardiac troponin T and cardiac troponin I does not 
improve the determination of patients with acute myocardial infarction. 
 
What are the clinical implications? 
• Combining cardiac troponin T and cardiac troponin I may contribute to a clinically 
relevant 3-to-6-fold increase in the number of rule-outs after a single blood draw at 
presentation compared to the current ESC 0/3 hour algorithms.  
• The increased rule-out of myocardial infarction at presentation may reduce the number of 
patients that have to wait for a consecutive cardiac troponin measurement, and may 
therefore favorable impact resource use and overcrowding in the emergency department.  
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Introduction 
Approximately 10% of all patients seeking medical attention at the emergency department (ED) 
report chest discomfort, a complaint that reflects many potential etiologies including acute 
myocardial infarction (AMI) 1. Rapid identification of patients with AMI is of profound clinical 
importance for fast initiation of medical treatment and management 2. In addition, rapid rule-out 
of patients without AMI can overcome prolonged patient anxiety, unnecessary resource use and 
overcrowding in the ED 3–7. Despite major improvements in diagnostic accuracy due to the 
introduction of high-sensitivity cardiac troponin (hs-cTn) assays and data-driven optimized 
diagnostic algorithms, rapid, accurate and safe rule-out based on a single measurement of hs-cTn 
is still possible only in a minority of patients 2,3,8,9.  
 Current guidelines recommend measurement of one of the cardiac specific isoforms of 
the cardiac troponin (cTn) complex: cTnI or cTnT 2,10. The development of high-sensitivity 
methods for the measurements of cTnT and cTnI concentrations has allowed the delineation of 
pathophysiological and analytical differences between cTnT and cTnI. First, hs-cTnT plasma 
concentrations exhibit a diurnal rhythm, while (hs)-cTnI does not 11. Second, hs-cTnT 
concentrations seem to be a stronger predictor of death as compared with hs-cTnI 
concentrations12. Third, cTnI seems to be released from injured cardiomyocyte slightly earlier 
and possibly by less intense injury as compared with cTnT 12. Fourth, the association with renal 
dysfunction is stronger for cTnT clearance than for cTnI 13. Fifth, hemolysis, which is common 
in blood samples taken in the ED, seems to increase cTnI concentrations, but decrease cTnT 
concentrations 14. Sixth, while analytically false positive results overall seem rare with both hs-
cTnT and hs-cTnI, they can be triggered by the re-expression of embryonic cTnT in the skeletal 
muscle of patients with neuromuscular disorders for hs-cTnT and heterophilic antibodies to cTnI 
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for hs-cTnI 15. Combining two signals of cardiomyocyte damage, hs-cTnT and hs-cTnI, might 
overcome some individual pathophysiological and analytical limitations and thereby increase 
diagnostic accuracy for AMI with a single blood draw 11,16,17. Despite differences in biochemical 
characteristics and release kinetics 18,19, a recent direct comparison between hs-cTnI and hs-cTnT 
showed similar, high diagnostic accuracy for AMI emphasizing the similarities between both 
isoforms 12. Based on the observation of an imperfect correlation between blood concentrations 
of cTnT and cTnI in chronic and acute disorders 20,21, and in analogy to the quantification of 
renal function using creatinine and cystatin C, where the combination of two parameters 
associated with the same pathophysiological process but influenced by distinct factors lead to a 
more precise and accurate indicator 22, we hypothesize that combining hs-cTnI and hs-cTnT 
concentrations will overcome independent pathophysiological, pre-analytical and analytical 
differences of the individual molecules, and might therefore have higher diagnostic accuracy for 
AMI than either hs-cTnI or hs-cTnT alone. This hypothesis was tested in two large prospective 
multicenter diagnostic studies. 
 
Methods 
The data and study materials will not be made available to other researchers for purposes of 
reproducing the results or replicating the procedure. The analytic methods will be available upon 
request.  
Patients and setting 
The combination of hs-cTnI and hs-cTnT for the diagnosis of AMI was investigated in two 
diagnostic cohorts; The primary cohort was the Advantageous Predictors of Acute Coronary 
Syndrome Evaluation (APACE) study 3,12,23,24, and the secondary (external validation) cohort 
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was the New Zealand-Australia combined data from the multicentre 2-Hour Accelerated 
Diagnostic Protocol to Assess Patients Witch Chest Pain Symptoms Using Contemporary 
Troponins as the Only Biomarker (ADAPT) study 25, the ADAPT-RCT, and the Emergency 
Department Chest Pain Score (EDACS)-RCT 26,27. For convenience we will refer to this 
combined cohort as the ADAPT cohort. 
APACE is an ongoing prospective international multicenter diagnostic study that enrolls 
patients presenting to the ED with acute chest discomfort with an onset of peak within the last 12 
hours. Patients are enrolled regardless of their renal function. Only patients with terminal kidney 
failure on chronic dialysis are excluded. This analysis contains data of patients enrolled between 
April 2006 and May 2013 who had a final diagnosis adjudicated by two independent 
cardiologists (n=3029). For this analysis, patients were excluded if hs-cTnI or hs-cTnT blood 
concentrations at presentation were not available (n=661), if the final adjudicated diagnosis was 
ST-elevation myocardial infarction (STEMI) (n=74), or if the final diagnosis remained unclear 
after adjudication and at least one (hs)-cTn level was elevated (possibly indicating the presence 
of AMI) (n=69).  
In the ADAPT cohort, patients with at least 5 min of symptoms consistent with acute 
coronary syndrome 28, but without ST-segment elevation, were enrolled at two EDs in Brisbane, 
Australia and Christchurch, New Zealand between November 2007 and July 2014. 
Both studies were carried out according to the principles of the Declaration of Helsinki, 
approved by the local ethics committees, and registered at clinicaltrial.gov (APACE: 
NCT00470587) or at the Australia-New Zealand Clinical Trials Registry (ADAPT: 
ACTRN12611001069943, ADAPT-RCT: ACTRN12610000766011, EDACS-RCT: 
ACTRN12613000745741). Written informed consent was obtained from all patients.  
 by guest on June 21, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.032003 
7 
Routine clinical assessment 
In both cohorts, patients underwent routine clinical assessment that included medical history, 
physical examination, standard blood tests including serial measurements of local (hs)-cTn, 12-
lead ECG, chest radiography, continuous ECG rhythm monitoring and pulse oximetry. 
Management of patients was left to the discretion of the attending physician.  
Adjudicated final diagnosis 
In the APACE cohort, adjudication of the final diagnosis was performed by two independent 
cardiologists at the core laboratory (University Hospital Basel) applying the universal definition 
of AMI 29 using two sets of data: first, all available medical records obtained during clinical care 
including history, physical examination, results of laboratory testing (including serial clinical 
(hs)-cTn concentrations, radiologic testing, ECG, echocardiography, cardiac exercise test, lesion 
severity and morphology in coronary angiography - pertaining to the patient from the time of ED 
presentation to 90-day follow up; second, study-specific assessments including detailed chest 
pain characteristics using 34 predefined criteria, serial hs-cTnT blood concentrations obtained 
from study samples, and clinical follow-up by telephone and/or mail. In situations of 
disagreement about the diagnosis, cases were reviewed and adjudicated in conjunction with a 
third cardiologist. These procedures were comparable to those in the ADAPT cohort, where the 
adjudication of the final diagnosis was performed by two independent cardiologists blind to 
results of the index-test biomarkers under investigation, but with knowledge of the clinical 
record, ECG, and serial cTnI results from routine care (details of adjudication are given in the 
Supplementary Data).   
 In both cohorts, AMI was defined and (hs-)cTn interpreted as recommended in the 
current guidelines 2,30,31.  In brief, AMI was diagnosed when there was evidence of myocardial 
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necrosis in association with a clinical setting consistent with myocardial ischemia. Myocardial 
necrosis was diagnosed by at least one cTn value above the 99th percentile (or for the 
conventional cTn assays above the 10% imprecision value if not fulfilled at the 99th percentile) 
together with a significant rise and/or fall. The criteria used to define a rise and/or fall in 
conventional cTn and hs-cTnT are described in detail in the method section in the data 
supplement. All other patients were classified in the categories of unstable angina (UA), Non 
Cardiac Chest Pain (NCCP), cardiac but non-coronary disease (e.g. tachyarrhythmias, 
perimyocarditis), and symptoms of unknown origin with normal concentrations of hs-cTnT. 
Measurement of hs-cTnT and hs-cTnI 
After centrifugation, serum was frozen at -80°C until measurement with hs-cTn assays. Hs-cTnI 
was measured by using the ARCHITECT High Sensitive STAT Troponin I assay (Abbott 
Laboratories). According to the manufacturer, the 99th percentile concentration is 26.2 ng/L with 
a corresponding coefficient of variation (CV) of <5% 32. Hs-cTnT was measured with the Roche 
hs-cTnT assay. The 99th percentile among healthy subjects is 14 ng/L, with a 10% analytical 
variation at 13 ng/L 33. Data presented here were not affected by the 2010–2012 hs-cTnT low-
end shift in APACE and appropriately corrected in ADAPT 34–36. Calculation of the glomerular 
filtration rate (eGFR) was performed using the abbreviated Modification of Diet in Renal 
Disease (MDRD) formula 37.  
Statistical analysis 
We evaluated the diagnostic accuracy and performance of the combined hs-cTnI and hs-cTnT 
measurement in two different ways: First, we examined sum, product and ratio. Second, we 
derived and tested a combination algorithm of hs-cTnI and hs-cTnT. Data are expressed as 
median ± interquartile range (IQR) for continuous variables and as numbers (n) and percentages 
 by guest on June 21, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.032003 
9 
(%) for categorical variables. Continuous variables were compared with the Mann-Whitney U 
test, and categorical variables were compared by use of the Pearson χ2 test. Cohen’s kappa 
statistic was used to examine the agreement between rule-in and rule-out at presentation based on 
hs-cTnT and hs-cTnI according to the two diagnostic algorithms recommended with a class I 
recommendation in the current European Society of Cardiology (ESC) guidelines: the 0/3h-hs-
cTn-algorithm and the 0h/1h-hs-cTn-algorithm 2. Sum, product and ratio were calculated from 
raw data. Undetectable low concentrations were assigned the concentration 0.1ng/L. Binary 
logistic regression analyses were used to calculate predicted probabilities for combined test 
variables.  
 Receiver-operating characteristics (ROC) curves were constructed to assess diagnostic 
performance at presentation and 1h after initial presentation including the absolute change value. 
Diagnostic accuracy was reported as the area under the ROC curve (AUC) and the corresponding 
95% confidence intervals (95% CI). The comparison of dependent and independent AUCs was 
performed as recommended by Hanley and McNeil 38 and for nested models with the comparison 
of -2 likelihood ratios as appropriate. 0h and 0h/1h serial sampled hs-cTn blood concentrations 
were combined to represent the current gold standard of clinical care as suggested in the 2015 
ESC guidelines 2. Furthermore, integrated discrimination improvement (IDI) was calculated 39.  
 For the determination of optimal cut-off values for sum, product and ratio (minimal 
negative predictive value (NPV) of 99.6% and a positive predictive value (PPV) of 75.0%, 
respectively, to match the performance of the 0h/1h-hs-cTn-algorithm 2,40,41, the cohort was 
randomly divided in a derivation (80% of patients) and a validation sub-cohort (20% of patients).  
 For the cut-off values in the combination algorithm, the optimal rule-out combination was 
that which maximized the percentage ruled-out at a sensitivity of 99% and the optimal rule-in 
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combination was that which maximized the percentage ruled-in at a PPV of 75%. We determined 
the optimal combination of hs-cTn thresholds based on a smoothed average of 500 bootstraps of 
the original cohort, in which we varied the hs-cTn threshold for each troponin assay in steps of 
0.1 ng/L. This methodology is more extensively described in the methods supplement. We used 
an ‘AND’-approach to ensure a safe early rule-out, and an ‘OR’-approach to maximize rule-in.  
 All hypothesis testing was two-tailed, and values of p<0.05 were considered statistically 
significant. We did not adjust for multiple testing. We did not adjust for multiple testing. 
Statistical analyses were performed with SPSS for Windows 23.0 (SPSS Inc), MedCalc 9.6.4.0 
(MedCalc software) and R version 3.2.4 (with packages ‘boot’ v1.3-18 and ‘fields’ v8.10). 
 
Results 
Distribution of hs-cTn concentrations at presentation in patients with suspected AMI 
Baseline characteristics of 2225 patients in the APACE cohort presenting to the ED with 
suspected AMI are shown in Supplementary Table 1. The adjudicated final diagnosis was AMI 
(NSTEMI) in 18% of patients (85% had type I and 15% type II AMI), UA in 10%, cardiac but 
not coronary artery disease in 14%, NCCP in 54%, and symptoms of unknown origin in 5%. 
AMI patients had higher concentrations of hs-cTnI and hs-cTnT at presentation compared with 
the no-AMI group (hs-cTnI median 115.2 ng/L (IQR: 21.7–632.9) vs. 3.5 ng/L (IQR: 2.2–7.2) 
P<0.001; hs-cTnT median 64.1 ng/L (IQR: 28.0–152.4) vs. 7.0 ng/L (IQR: 4.0–12.4) P<0.001; 
Supplementary Table 2 and Supplementary Figure 1). The correlation between hs-cTnI and hs-
cTnT concentrations at presentation was high (r=0.89) (Figure 1).  
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Diagnostic performance of hs-cTn concentrations measured at presentation according to 
the ESC 0/3-hour algorithm 
In the APACE cohort 721 of 2225 patients (32.4%) presented ≥6h after onset of chest pain and 
therefore could be assessed by the late-presenter part of the ESC 0/3h algorithm with a single 
blood draw. Using hs-cTnT, AMI could be ruled-out in 441 patients (19.8% of overall cohort, 
61.2% of late-presenters) by a baseline hs-cTn below the 99th percentile, 4 AMI`s were missed. 
Adding the clinical information (GRACE score <140 and pain free) resulted in 1 missed AMI 
and therefore in a sensitivity of 99.3% (95%Cl 96.2-100%) and a NPV of 99.4% (95%Cl 96.8-
100%).  
 Using hs-cTnI, in 539 patients (24.2% of overall cohort, 74.8% of late-presenters) AMI 
could be ruled-out by a single blood draw at presentation, 21 AMI`s were missed. Adding the 
clinical information reduced the number to 3 missed AMI`s; sensitivity 97.9% (95%Cl 94.0-
99.6%) and NPV 98.5% (95%Cl 95.7-99.7%). The agreement on patient allocation between hs-
cTnI and hs-cTnT for rule-out at presentation was good (κ=0.90) (Supplementary Table 3). 
Diagnostic performance of hs-cTn concentrations measured at presentation according to 
the ESC 0/1-hour algorithm 
AMI could be ruled-out in 149 (6.7%, sensitivity 100%, NPV 100%) and 235 (10.6%, sensitivity 
100%, NPV 100%) patients after a single blood draw at presentation, using hs-cTnI and hs-
cTnT, respectively. Direct rule-in could be achieved in 331 (14.9%, specificity 95.6%, PPV 
75.5%) and 273 (12.3%, specificity 2.4%, PPV 84.2%) subjects, using hs-cTnI or hs-cTnT, 
respectively. The agreement on patient allocation at presentation between hs-cTnI and hs-cTnT 
was moderate for rule-out (κ=0.42) and good for rule-in (κ=0.79)  (Supplementary Tables 4 and 
 by guest on June 21, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.032003 
12 
5). Using the 0/1-hour algorithm 77-78% of patients need a second cardiac troponin 
measurement.  
Diagnostic performance of combined hs-cTnI and hs-cTnT concentrations measured at 
presentation 
The diagnostic accuracy in the APACE cohort, as quantified by AUC was evidently lower for the 
ratio than for the sum, product, or combination of hs-cTn and for the individual isoforms alone 
(Table 1 and Figure 2). Addition of a second isoform to 0h hs-cTn led to a numerically small 
increase in AUC above that for hs-cTnT alone, but not for hs-cTnI alone. Furthermore, addition 
of a combined measurement at presentation to the 0h and 0h/1h change concentrations led to a 
numerically small, but statistically significant improvement in diagnostic accuracy of hs-cTnI, 
but not of hs-cTnT (Supplementary Table 6). Reclassification statistics (IDI) did not uniformly 
show incremental value of combining cardiac troponins at presentation when applied to the 
APACE cohort (Supplementary Tables 7). Diagnostic performance did not increase when two 
different cardiac troponin I signals were combined (Siemens c-TnI Ultra, Beckman hs-cTnI and 
Siemens hs-cTnI Vista; Supplementary tables 8, 9 and 10). Comparable results were found when 
hs-cTnI and hs-cTnT were combined using logistic regression analysis (methods supplement, 
supplementary results).  
Early allocation based on sum and product 
We examined the use of sum and product on the allocation of patients at presentation. In a 
randomly selected derivation cohort of 1799 patients (313 AMI, 1486 no AMI), thresholds for 
rule-out and rule-in achieving a NPV of at least 99.6% and a PPV of 75.0%, respectively, were: 
rule-out cut-off for the sum of 9 ng/L and for the product of 18 ng2/L2 (NPV both 100% (95% 
CI, 99.4–100%), and a rule-in cut-off for the sum of 99 ng/L and for the product of 1608 ng2/L2 
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(PPV sum 75.1% (95% CI 69.3% – 80.3%), PPV product 75.1% (95% CI 69.5%–80.1%)). When 
these cut-off values were applied to the internal validation cohort of 426 patients (85 AMI, 341 
no AMI), we found comparable results for sum (rule-out: sensitivity 100% (95.8%-100%), NPV 
100% (97.5%-100%); rule-in: specificity 96.8% (94.3%-98.4%), PPV 83.6% (72.4%-91.6%) and 
product (rule-out: sensitivity 100% (95.8%-100%), NPV 100% (97.5%-100%); rule-in: 
specificity 96.8% (94.3%-98.4%), PPV 83.6% (72.4%-91.6%); Tables 2 and 3. Application of 
these cut-off values in the original cohort (APACE) would cause a 3-to-5-fold increase in the 
number of rule-outs at presentation as compared to the 2015 ESC algorithms. This would 
decrease the percentage of patients that require a second cardiac troponin measurement one hour 
later from 77-78% to 50-52%.   
 When these cut-off values were applied to the external validation cohort (for patient 
characteristics see Supplementary Table 11) of 2537 patients (408 AMI, 2129 no AMI), we 
found comparable results for sum (rule-out: sensitivity 99.0% (97.5%-99.7%); NPV 99.6%; 
(99.0%-99.9%) rule-in: specificity 98.2% (97.5%-98.7%); PPV 87.5% (83.3%-91.0%)) and 
product (rule-out: sensitivity 98.5% (96.8%-99.5%), NPV 99.4% (98.8%-99.8%); rule-in: 
specificity 98.0% (97.3%-98.5%), PPV 83.6% (83.2%-90.6%)); Tables 2 and 3. Applying sum 
and product for rule-in and rule-out would lead to 45-49% of subjects that require a second 
cardiac troponin measurement after an hour in the ADAPT cohort.  
 Details of the subjects that were falsely ruled-out using sum and product are reported in 
supplemental table 12 and 13. 
Early allocation based on a combination algorithm consisting of hs-cTnI and hs-cTnT 
The optimal cut-off combination with an NPV of at least 99.6% was hs-cTnT < 9.8 ng/L and hs-
cTnI < 4.8 ng/L. From a pragmatic point of view, we rounded these cut-off concentrations down 
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to hs-cTnT <9 ng/L and hs-cTnI <4 ng/L. In the original cohort (APACE) these thresholds 
combine to rule-out 48.4% of patients, to a 4-to-6-fold increase in the number of rule-outs at 
presentation than the ESC 0/3h algorithm. In the external validation cohort the optimal rule-out 
combination would rule-out >50% of subjects (sensitivity 98.8% (97.2%-99.6%), NPV 99.5% 
(98.9%-99.9%)). The NPV in the external validation cohort was lower than the one in the 
original cohort (Table 4). Details of the subjects that were falsely ruled-out using this 
combination algorithm are reported in Supplemental Table 12 and 13.  
 The optimal cut-off combination for rule-in was hs-cTnT ≥ 57 ng/L OR hs-cTnI ≥ 54 
ng/L which in the APACE cohort ruled-in 259 (65.1%) of AMI patients. In the external 
validation cohort, 293 (71.8%) patients with a final diagnosis of AMI subjects would be ruled in 
(specificity 97.4% (93.7%-95.6%), PPV 84.0% (79.7%-87.6%)) (Table 5). This would lead to 
43% of patients that require a second cardiac troponin measurement after an hour.   
 
Discussion 
We evaluated four methods to combine cTnI and cTnT for the early diagnosis of AMI in two 
large prospective diagnostic multicenter studies, and report three major findings.  
First, the number of direct rule-outs at presentation using the algorithms of the current 
ESC guidelines2 is limited (7-13% of subjects without an AMI) and assay-dependent. Second, 
the difference in diagnostic accuracy between the combinations of the cTn measured by the two 
assays and a cTn measurement by either assay alone is numerically small (except for when 
combined as a ratio). In addition, the results of the reclassification statistics indicated that the 
application of two cTn isoforms at presentation may add incremental value, but that this is not 
the case for the sum and product when applied to the whole cohort. Third, combining cardiac hs-
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cTnI and hs-cTnT, using the sum and product or a combination algorithm, achieved a very high 
NPV and lead to a 3-to-6-fold increase in the number of rule-outs after a single blood draw 
compared to the ESC algorithms.  
 The findings from this study corroborate and extend previous work aiming to further 
improve the safety and efficacy of the rule-out and rule-in of AMI among patients presenting 
with acute chest discomfort to the ED 2–4,7,8,42–45. Including two large meta-analyses providing 
exact estimates for the performance of single measurement rule-out strategies using very low 
concentrations of hs-cTnT and hs-cTnI 46,47.  To the best of our knowledge this work is the first 
systematic approach testing the clinical utility of combinations of hs-cTnI and hs-cTnT, the two 
most accurate biochemical signals in the early diagnosis of AMI 2–4,43–45. While there is broad 
agreement that hs-cTnI or hs-cTnT should be used as a key component in any AMI rule-out 
algorithm 2,7,10,48,49, it has remained unclear whether a second biochemical signature could 
provide enough incremental value to potentially justify routine clinical use. 
 While when used in conjunction with less sensitive cTn assays, some additional 
biochemical signals including copeptin and heart-type fatty acid-binding protein (hFABP) were 
able to provide incremental diagnostic value, this was no longer the case when using hs-cTnT or 
hs-cTnI as recommended in current guidelines 50–55. The only additional analyte that recently was 
suggested to possibly provide incremental diagnostic value even if using hs-cTnT is cardiac 
myosin-binding protein C, a quantitative marker of cardiomyocyte injury that seems even more 
rapidly released from injured cardiomyocytes as compared to hs-cTnT and hs-cTnI 56. 
 The novel concept investigated in this study was based on recent studies documenting 
that there could be remarkable differences between the cTnI and the cTnT signal, and the 
moderate agreement between clinical decisions made on these concentrations 20,57,58. We 
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hypothesized that combining the two biochemical signals might overcome independent 
pathophysiological, pre-analytical and analytical differences between the individual molecules 
such as (auto)antibodies and suggested interference with troponin released from skeletal 
muscle12,15,59,60, and might therefore have higher diagnostic accuracy for AMI than either cTnI or 
cTnT alone.  
This study shows that combining hs-cTnI and hs-cTnT may contribute to a clinically 
relevant increase in the number of rule-outs at presentation. The small increase in false-negative 
results when the derived thresholds were applied in the external validation cohort raises the 
question what is considered a still acceptable number of false rule-ins and rule-outs61. 
Furthermore, it illustrates the outlier-dependency of the determination of very low cut-off values, 
and advocates the use of extended (pooled) cohorts and the recalibration of cut-off values for the 
determination of more universally applicable decision rules 62. A second point that merits 
attention are the, at first sight contrary, unconvincing results of the diagnostic accuracy and 
reclassification statistics. Because the AUC is already very high for either hs-cTn alone and 
because it is based on ranking with the large numbers of patients below the LoD having the same 
rank, the signal from an additional biomarker to increase the AUC would need to be massive and 
the biomarker itself may need to be a better marker even than hs-cTn. These findings are of 
limited additional value for the whole population, whereas combing hs-cTnI and hs-cTnT might 
be especially valuable in patients with low hs-cTn concentrations at presentation. Another reason 
for this discrepancy might be the three-group (rule-out, observational, rule-in) approach that is 
used for the diagnosis of AMI and its outlier dependency. 
 The clinical implementation of a dual-marker approach combining cTnI and cTnT would 
likely be associated with substantial logistic obstacles since no diagnostic company currently is 
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able to provide both hs-cTnT and hs-cTnI assays on the same laboratory platform. In addition, 
most hospitals currently do not have analyzers for both analytes running on a 24/7 basis or even 
have only the platform for one of the assays at all. Therefore, the cost-effective clinical 
implementation of the dual-marker approach would require either additional investment in 
infrastructure by the laboratories (installing another platform) and/or collaboration among 
diagnostic companies for the provision of both hs-cTnT and hs-cTnI assays on the analyzer that 
is used for clinical chemistry routine. The clinical implementation of a dual-marker approach 
combining cTnI and cTnT would likely be associated also with substantial educational efforts for 
clinicians working in the ED, as two similar, yet different analytes with different clinical 
decision values would then be in clinical use at the same institution.  Nevertheless, rapid and safe 
clinical decision making based on a single hs-cTn measurement at presentation seems to be 
approaching its limits, and the exploration of new diagnostic strategies including combinations 
of biomarkers, risk-assessment scores, or imaging seems to be indicated 8. From this point of 
view, overcoming these logistic obstacles by close collaboration between diagnostic companies, 
hospital laboratories, medical doctors and researchers would be able to provide substantial 
medical value for patients and physicians, and economic value for hospitals and the health care 
system in general. Future studies are necessary to identify the best strategy and to better quantify 
the possible clinical benefit associated with the combination of cTnI and cTnT. Considering the 
relevant unmet clinical need as quantified by the high percentage of rule-out mismatches, the 
substantial increase in early rule-outs compared to the current ESC 0h/1h-algorithm and the 
substantial cost savings associated with reductions in the length of stay in the ED 63, dedicated 
economic analyses can be expected to show substantial reductions in time to decision, time to 
discharge, and therefore treatment costs. Consecutive studies to objectify these claims are 
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indicated. Furthermore, it is important to highlight that despite the very high diagnostic accuracy, 
hs-cTn and their combinations will always have to be used clinically only in conjunction with 
full clinical assessment including detailed patient history, physical examination, and the ECG 2. 
 Some limitations of this study merit consideration. First, the central adjudication by two 
independent cardiologists based on the clinical dataset including cardiac imaging and serial 
measurements of the local (hs)-cTn and the study-specific dataset including 34 chest pain 
characteristics, serial measurements of hs-cTnT, and follow-up in the APACE study represents 
the highest quality possible in a diagnostic study. However, it possibly introduced a very small 
but unavoidable disadvantage for hs-cTnI regarding diagnostic accuracy. This is at large 
counterbalanced by the use of (h)s-cTnI for the adjudication ADAPT, as this possibly introduced 
a very small but unavoidable disadvantage for hs-cTnT regarding diagnostic accuracy. Second, 
patients with terminal kidney failure on chronic dialysis were excluded from APACE. 
Accordingly, we cannot comment on the possible clinical utility of the combination approach in 
these vulnerable patients. Third, the method we used to determine the cut-off values for the 
combination algorithm could not produce very smooth curves for rule-in. Alternative methods 
may therefore provide better results for rule-in. Fourth, an alternative approach to combine both 
cardiac troponins would be logistic regression. As shown in the supplemental, this lead to 
comparable results. Nevertheless, the strong correlation between cardiac troponins may lead to 
spurious beta coefficients, and therefore we did not use this method for our primary results 64.  
 In conclusion, diagnostic strategies combining cTnI and cTnT measurements, sum, 
product or a combination algorithm, may significantly increase the number of patients eligible 
for very early and safe rule-out, but does not seem helpful for the rule-in of AMI.  
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Table 1. Diagnostic accuracy of hs-cTnI, hs-cTnT, the combination, sum, product and ratio for 
the diagnosis of AMI at presentation 
 
Parameters AUC (95% CI) Compared with  
hs-cTnI alone 
(p-value) 
Compared with  
hs-cTnT alone 
(p-value) 
hs-cTnI alone 0.93  
(0.92 – 0.94 ) 
 0.714 
hs-cTnT alone 0.93  
(0.92 – 0.94) 
0.714  
hs-cTnI <4ng/L & 
hs-cTnT <9ng/L 
0.93  
(0.92 – 0.94) 
0.789 0.002 
Sum  
(hs-cTnI + hs-cTnT) 
0.94  
(0.93 – 0.95) 
0.053 0.114 
Product  
(hs-cTnI x hs-cTnT) 
0.94  
(0.93 – 0.95) 
0.007 0.078 
Ratio  
(hs-cTnI/hs-cTnT) 
0.79  
(0.78 – 0.81) 
<0.001 <0.001 
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Table 2. Performance of sum and product for rule-out.  
 
 Original cohort  
(N=2225; 398 AMI, 1827 NO AMI) 
External validation cohort 
(N=2537; 408 AMI, 2129 NO AMI) 
Sum < 9 ng/L   
All subjects 746 (33.5%) 988 (38.9%) 
AMI 0 (0.0 %) 4 (1.0%) 
No AMI 746 (40.8 %) 984 (46.2%) 
NPV 100%  
(99.5% - 100%) 
99.6% 
(99.0% – 99.9%) 
Product < 18 ng2/L2   
All subjects 782 (35.1%) 1047 (41.3%) 
AMI 0 (0.0 %) 6 (1.5%) 
No AMI 782 (42.8 %) 1041 (48.9%) 
NPV 100%  
(99.5% - 100%) 
99.4% 
(98.8% – 99.8%) 
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Table 3. Performance of sum and product for rule-in.  
 
 Original cohort  
(N=2225; 398 AMI, 1827 NO AMI) 
External validation cohort 
(N=2537; 408 AMI, 2129 NO AMI) 
Sum > 99 ng/L   
All subjects 324 (14.6%) 312 (12.3%) 
AMI 249 (62.2%) 273 (66.9%) 
No AMI 75 (4.1%) 39 (1.8%) 
PPV 76.9% 
(71.8% – 81.3%) 
87.5% 
(83.3% - 91.0%) 
Product > 1608 ng2/L2   
All subjects 340 (15.3%) 337 (13.3%) 
AMI 261 (65.6 %) 294 (72.1%) 
No AMI 79 (4.3 %) 43 (2.0%) 
PPV 76.8% 
(71.9% – 81.2%) 
87.2% 
(83.2% - 90.6%) 
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Table 4. Performance of the combination approach for rule-out. 
 
 Original cohort  
(N=2225; 398 AMI, 1827 
NO AMI) 
External validation cohort 
(N=2537; 408 AMI, 2129 
NO AMI) 
hs-cTnI < 4 ng/L AND hs-cTnT <9 ng/L   
All subjects 886 (39.8%) 1088 (42.9%) 
AMI 1 (0.3%) 5 (1.2%) 
No AMI 885 (48.4%) 1083 (50.9%) 
NPV 99.9%  
(99.2% – 100%) 
99.5%  
(98.9% – 99.8%) 
hs-cTnI < 4 ng/L   
All subjects 1021 (45.9%) 1210 (47.7%) 
AMI 5 (1.3%) 6 (1.5%) 
No AMI 1016 (55.6%) 1204 (56.6%) 
NPV 99.5%  
(98.9% – 99.8%) 
99.5%  
(98.9% – 99.8%) 
hs-cTnT <9 ng/L   
All subjects 1117 (50.2%) 1440 (56.8%) 
AMI 12 (3.0%) 16 (3.9%) 
No AMI 1105 (60.5%) 1424 (66.9%) 
NPV 98.9%  
(98.1% - 99.4%) 
98.9%  
(93.7% – 97.7%)  
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Table 5. Performance of the combination approach for rule-in. 
 
 Original cohort  
(N=2225; 398 AMI, 1827 
NO AMI) 
External validation cohort 
(N=2537; 408 AMI, 2129 
NO AMI) 
hs-cTnI ≥ 54 ng/L OR hs-cTnT ≥ 57 ng/L   
All subjects 348 (15.6%) 349 (13.8%) 
AMI 259 (65.1%) 293 (71.8%) 
No AMI 89 (4.9%) 56 (2.6%) 
PPV 74.4% (69.6% – 78.8%) 84.0% (79.7% - 87.6%) 
hs-cTnI ≥ 54 ng/L   
All subjects 327 (14.7%) 322 (12.7%) 
AMI 247 (62.1%) 283 (69.4%) 
No AMI 80 (4.4%) 39 (1.8%) 
PPV 75.5% (70.4% - 80.0%) 87.9% (83.8% - 91.2%) 
hs-cTnT ≥ 57 ng/L   
All subjects  256 (11.5%) 240 (9.5%) 
AMI 218 (54.8%) 206 (50.5%) 
No AMI 38 (2.1%) 34 (1.6%) 
PPV 85.2% (80.1% - 89.2%) 85.8% (80.8% - 90.0%) 
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Figure Legends 
 
Figure 1. Log (base 10)-scale scatter plot of hs-cTnT and hs-cTnI at presentation in the 
APACE cohort 
Log-scale scatter plot displaying hs-cTnI and hs-cTnT concentrations at presentation in the 
APACE cohort (n=2225). The correlation coefficient is high (Pearson’s r=0.89).  
 
Figure 2. ROC curves of the diagnostic performance of high-sensitivity cTn and their ratio, 
sum and product for NSTEMI in the APACE cohort 
Diagnostic performance of high-sensitive cTn for non-ST segment myocardial infarction at 
presentation to the emergency department with acute chest pain. Receiver-operating-
characteristic curves show the diagnostic accuracy of high-sensitive cardiac troponins I and T, 
their ratio, sum and product.  
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Methods supplement 
Use of local conventional cTn values and hs-cTnT values for adjudication of final diagnoses in APACE 
cohort 
The cTn assays used clinically in most of the participating institutions changed during the study from a 
conventional cTn assay to the hs-cTnT assay. In this analysis 40% of patients in APACE were managed 
clinically with a high-sensitivity troponin. In order to take advantage of the higher sensitivity and higher 
overall diagnostic accuracy offered by the hs-cTnT assay, patients were adjudicated using the hs-cTnT 
values in all patients. In patients in whom clinically a conventional cTn assay was used, the conventional 
cTn values and the hs-cTnT values were available for the adjudication. In patients in whom clinically 
the hs-cTnT assay was used, only the hs-cTnT values were available for the adjudication. 
The following conventional cTn assays were used: For the Roche cTnT 4th generation assay, the 10% 
CV level is 0.035ug/l. The laboratories of the participating sites reported only two decimals; therefore 
0.04ug/l was used as a cut-off for myocardial necrosis. In order to fulfil the criteria of a significant 
change (30% of 99th percentile or 10% CV level), a patient would e.g. need to have a level of <0.01ug/l 
at presentation and 0.04ug/l at 6h. A patient would also qualify if the first level is 0.02ug/l and the 
second 0.04ug/l. A patient would not fulfil the criteria if the first level is 0.03ug/l and the second is 
0.04ug/l. If the first level is 0.04ug/l, the second level needs to be at least 0.06ug/l.  
For the Abbott Axsym cTnI ADV, the 10% CV level is 0.16ug/l. A patient having 0.16ug/l at presentation 
would meet the criteria for significant change if the second was ≥0.21ug/l. A patient having <0.12ug/l 
at presentation (limit of detection) would qualify if the second is >0.16ug/l.  
For the Beckmann Coulter Accu cTnI, the 10% CV level is 0.06ug/l. A patient having 0.06ug/l at 
presentation would qualify if the second is ≥0.08ug/l. A patient having 0.05 at presentation would 
qualify if the second is 0.07ug/l, but not 0.06ug/l. A patient having undetectable cTnI (cTnI<0.01ug/l) 
at presentation would qualify if the second is ≥0.06ug/l. 
For hs-cTnT the 99th percentile (14ng/l) was used as cut-off for myocardial necrosis 1,2. Absolute 
changes in hs-cTnT were used to determine significant changes based on the diagnostic superiority of 
 
 
absolute over relative changes 3,4. Based on studies of the biological variation of cTn 5,6 as well as on 
data from previous chest pain cohort studies 7,8, a significant absolute change was defined as a rise or 
fall of at least 10ng/l within six hours. In patients, in whom a 6 hour hs-cTnT level was not available, 
changes were assessed at earlier time points. In an assumption of linearity, an absolute change of 6ng/l 
within three hours was considered.  
 
Adjudication of final diagnosis in ADAPT cohort 
Outcomes were adjudicated independently by local cardiologists using predefined standardized 
reporting guidelines. Cardiologists had knowledge of the clinical record, ECG, troponin results and 
objective testing from standard care. A second cardiologist conducted a blind review of all ACS cases 
and 10% of non-ACS cases. In cases of disagreement, endpoints were agreed by consensus.  
 Diagnosis of AMI was according to international guidelines and based on evidence of 
myocardial necrosis and ischemia. Evidence of ischaemia included at least one of ECG changes or 
positive imaging results from exercise tolerance testing, myocardial perfusion scan, stress 
echocardiography, computed tomographic coronary angiography or coronary angiography during 
catheterization.  Necrosis was diagnosed based on a rise or fall of cardiac troponin concentration over 
at least six hours with at least one value above the 99th percentile of the normal reference range at a 
level of assay imprecision near to 10%. If the troponin was greater than the reference range but no 
rise or fall was recorded, other causes of raised troponin were considered. If no alternative cause for 
the troponin rise was apparent and if the clinical presentation was suggestive of ACS, an adjudicated 
diagnosis of AMI was made. 
 Emergency revascularisation was defined as PCI or CABG in a symptomatic patient where the 
clinical status includes either 1) ischaemic dysfunction (ongoing ischaemia despite maximal medical 
therapy, acute evolving myocardial within 24 hours before intervention or pulmonary oedema 
requiring intubation) or 2) mechanical dysfunction (shock with or without circulatory support). Urgent 
revascularisation included PCI or CABG that did not meet the emergency criteria above but was 
 
 
required during the same hospitalization to minimize chance of further clinical deterioration. Elective 
revascularization, or those procedures that could be deferred without increased risk of compromised 
cardiovascular outcome, were not included in the endpoint.  
 
Assumption of linearity of absolute changes of hs-cTnT within the first hours 
The assumption of linearity of absolute changes within the first hours is based on unpublished internal 
data as well as recent data from Ola Hammarsten et al. showing a near-linear increase in levels of hs-
cTnT with increasing time from symptom onset in their NSTEMI cohort 9.  
 
Determination of cut-offs for the combination algorithm 
We aimed to determine the safe, and optimal combination of hs-cTnI concentration and hs-cTnT 
concentration. A test was considered positive if either hs-cTn concentration was greater than or equal 
to an hs-cTn threshold for that troponin assay. We varied the hs-cTn threshold for each troponin assay 
in steps of 0.1 ng/L across the range from the LoD to 26 ng/L. At each combination of hs-cTn thresholds 
we calculated the sensitivity and specificity for the diagnosis of AMI. We created 500 bootstraps of the 
data, and to average the results we then fitted a smooth surface (thin plate spline) for sensitivity on 
the hs-cTnI threshold – hs-cTnT threshold grid from which we could determine the 99% sensitivity 
contour and contours for specificity. The optimal threshold was defined as the combination with 99% 
sensitivity and maximized specificity. 
 
Combining cardiac troponin T and cardiac troponin I using logistic regression 
In addition, we performed a logistic regression model for the index admission of AMI using a single 
blood draw at presentation. The log-10-transformed hs-cTnI and hs-cTnT concentrations were 
combined in a logistic regression model in order to calculate the probability of AMI for each patient. 
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Supplementary results 
 
Combining cardiac troponin T and cardiac troponin I using logistic regression 
Applying a logistic regression model (described in the methods supplement) to the original cohort 
(APACE) resulted in: p = 1/(1+exp(-XBeta)) where XBeta = -5.75 + 1.1 * log(hs-TnI) + 2.34* log (hs-TnT). 
The corresponding AUC was 0.940 (95%CI: 0.929 to 0.952).  
In the original cohort, the determined probability threshold (p) for a NPV of  99.5% was p=0.05. This 
resulted in a NPV of 99.5% (95% CI 98.9% to 99.8%) and allocation of 82.1% of patients to the rule-out 
category. The probability threshold of p=0.38 corresponded to a PPV of 75%, and led to a PPV of 75.5% 
(70.7% to 79.9%) and the allocation of 17.9% of patients to the rule-in category. 
When the beta coefficients that were derived from the logistic regression model in the original cohort 
were applied to the validation cohort (ADAPT), the AUC was 0.959 (95%CI: 0.949 to 0.959). Using the 
probability thresholds from the original cohort (p=0.05 and p=0.38 for rule-out and rule-in, 
respectively), the NPV was 99.3% (98.6% to 99.6%) and the PPV was 82.5% (78.2% to 86.2%). This 
would lead to the allocation of 83.9% and 16.1% of patients to the rule-out and the rule-in category, 
respectively.  
 
 
  
 
 
Supplementary Table 1. Baseline characteristics of patients in the APACE cohort 
Characteristic All AMI No AMI 
 n= 2225 n= 398 n= 1827 
Age, y 62 (49 – 75) 72 (61 – 80) 60 (47 – 73) 
Male sex, n (%) 1511 (68) 290 (73) 1221 (67) 
Risk factors, n (%)    
Hypertension 1382 (62) 318 (80) 1064 (58) 
Hypercholesterolemia 1110 (50) 272 (68) 838 (46) 
Diabetes Mellitus 384 (17) 108 (27) 276 (15) 
Current or previous smoking 1366 (61) 253 (64) 1113 (61) 
Family history 549 (25) 117 (29) 432 (24) 
History, n (%)    
Coronary Artery Disease 776 (35) 202 (51) 574 (31) 
Previous AMI 513 (23) 136 (34) 377 (21) 
Previous revascularisation 612 (28) 147 (37) 465 (26) 
Peripheral artery disease 141 (6) 56 (14) 85 (5) 
Previous stroke 122 (6) 39 (10) 83 (5) 
Body-mass index, kg/m2 26 (24 – 30) 26 (24 – 29) 26 (24 – 30) 
eGFR, ml·min-1·1.73m-2  85 (69 – 101) 73 (55 – 93) 87 (71 – 103) 
ECG changes, n (%)    
       ST segment depression 232 (10) 121 (30) 111 (6) 
       T wave inversion 296 (13) 100 (25) 196 (11) 
       LBBB 25 (1) 11 (3) 14 (1) 
Medication at presentation    
ASA 808 (36) 199 (50) 609 (33) 
Vitamin K antagonist 191 (9) 41 (10) 150 (8) 
β-blockers 770 (35) 174 (44) 596 (33) 
Statins 777 (35) 178 (45) 599 (33) 
ACEIs/ARBs 842 (38) 206 (52) 636 (35) 
Calcium antagonists 321 (14) 82 (21) 239 (13) 
Nitrates 257 (12) 85 (21) 172 (9) 
APACE denotes Advantageous Predictors of Acute Coronary Syndrome Evaluation; AMI, acute myocardial 
infarction; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; LBBB, left bundle branch block; 
ASA, acetyl salicylic acid; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker. 
Values are expressed in percentage or medians ± IQR. 
 
 
Supplementary Table 2. Hs-cTn concentrations at presentation in the APACE cohort 
 hs-cTnI (ng/L) hs-cTnT  (ng/L) Sum (ng/L) Product (ng2/L2) Ratio 
AMI (n=398) 115.2 (21.7 – 632.9) 64.1 (28.0 – 152.4) 184.2 (52.4 – 812.8) 7258 (596 – 91526) 1.84 (0.82 – 4.72) 
No AMI (n=1827) 3.5 (2.2 – 7.2) 7.0 (4.0 – 12.4) 10.6 (6.5 – 20.0) 23 (9 – 86) 0.57 (0.38 – 0.90) 
UA (n=216) 6.4 (3.6 – 12.1) 10.7 (6.9 – 16.0) 17.5 (11.1 – 29.6) 63 (25 – 199) 0.65 (0.42 – 1.12) 
Cardiac, non-coronary (n=307) 8.4 (3.4 – 28.6) 13.4 (7.0 – 29.0) 10.6 (23.3 – 59.5) 112 (24 – 727) 0.70 (0.45 – 1.31) 
NCPP (n=1202) 3.0 (1.9 – 5.1) 6.0 (3.9 – 9.7) 8.9 (5.9 – 15.1) 17 (8 – 47) 0.52 (0.36 – 0.81) 
Unknown (n=102) 2.9 (2.3 – 4.8) 5.8 (3.0 – 9.4) 8.8 (5.8 – 14.9) 17 (8 – 48) 0.58 (0.39 – 0.76) 
p-value (AMI compared with no AMI) p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
Median (IQR) 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 3. Baseline characteristics of patients in the ADAPT cohort 
Characteristic All AMI No AMI 
 n=2537 n=408 n=2129 
Age, y 60 (51 – 71)  59 ( 49 – 69) 69 (59 – 78)  
Male sex, n (%) 1535 (61) 292 (72) 1243 (58) 
Risk factors, n (%)    
Hypertension 1316 (52) 254 (62) 1062 (50) 
Hypercholesterolemia 1309 (52) 228 (56) 1081 (51) 
Diabetes Mellitus 377 (15) 81 (20) 296 (14) 
Current smoking 462 (18) 72 (18) 390 (18) 
Family history of CAD 1393 (55) 245 (60) 1148 (54) 
History, n (%)    
Previous AMI 627 (25) 128 (31) 499 (23) 
Previous PCI 525 (21) 85 (21) 440 (21) 
Previous CABG 219 (9) 55 (13) 164 (8) 
Peripheral artery disease 94 (4) 25 ( 6) 69 (3) 
Previous stroke 205 (8) 39 (10) 166 (8) 
Body-mass index, kg/m2 27 ( 24 – 31) 28 (24 – 31) 27 (24 – 31) 
ADAPT denotes Accelerated Diagnostic Protocol to Assess Patients Witch Chest Pain Symptoms Using 
Contemporary Troponins as the Only Biomarker; AMI, acute myocardial infarction; CABG, coronary artery bypass 
grafting; PCI, percutaneous coronary intervention. 
Values are expressed in percentage or medians ± IQR. 
 
 
 
 
  
 
 
Supplementary Table 4. Agreement on rule-out at presentation using the 0h/3h-algorithm in the 
APACE cohort 
 
  hs-cTnT 
  Rule-out* No rule-out 
hs-cTnI 
Rule-out* 132 (5.9%) 25 (1.1%) 
No rule-out 1 (0.0%) 2067 (92.9%) 
* if hs-cTnT < 14 ng/L or hs-cTnI < 26.2 ng/L, >6h after onset of symptoms and painfree, and GRACE score < 140 
 
Supplementary Table 5. Agreement on rule-out at presentation using the 0h/1h-algorithm in the 
APACE cohort 
 
  hs-cTnT 
  Rule-out* No rule-out 
hs-cTnI 
Rule-out* 98 (4.4%) 51 (2.3%) 
No rule-out 137 (6.2%) 1939 (87.1%) 
* if hs-cTnT < 5 ng/L or hs-cTnI < 2 ng/L and >3h after onset of symptoms 
 
Supplementary Table 6. Agreement on rule-in at presentation using the 0/1h-algorithm in the 
APACE cohort 
 
  hs-cTnT 
  Rule-in* No rule-in 
hs-cTnI 
Rule-in* 246 (11.1%) 85 (3.8%) 
No rule-in 27 (1.2%) 1867 (83.9%) 
* if hs-cTnT > 52 ng/L or hs-cTnI > 52 ng/L  
 
 
 
 
 
 
Supplementary Table 7. Diagnostic accuracy of hs-cTnT and hs-cTnI after the addition of the alternative signal or sum, product or ratio at presentation in 
the APACE cohort 
 Time point AUC (95% CI; SE) AUC (95% CI; SE)  
after addition of hs-
cTnI or hs-cTnT 
p-value AUC (95% CI;SE)  
after addition of 
sum 
p-value AUC (95% CI;SE) 
after addition of 
product 
p-value AUC (95% CI;SE)  
after addition of 
ratio 
p-value 
hs-cTnT 0h* 0.93 
(0.92 – 0.94; 0.009) 
0.94 
(0.93 – 0.95; 0.008) 
0.002 0.94 
(0.93 – 0.95; 0.009) 
0.006 0.94 
(0.93 – 0.95; 0.008) 
0.002 0.94 
(0.93 – 0.95; 0.008) 
0.002 
 0h + 1h† 0.96 
(0.95 – 0.97; 0.008) 
0.96 
(0.95– 0.97; 0.008) 
0.795 0.96 
(0.95 – 0.97; 0.008) 
0.838 0.96 
(0.95– 0.97; 0.008) 
0.795 0.96 
(0.95– 0.97; 0.008) 
0.795 
 0h + 0h/1h-delta† 0.95 
(0.93 – 0.96; 0.009) 
0.95 
(0.94 – 0.96; 0.009) 
0.142 0.95 
(0.94 – 0.96; 0.009) 
0.217 0.95 
(0.94 – 0.96; 0.009) 
0.142 0.95 
(0.94 – 0.96; 0.009) 
0.142 
hs-cTnI 0h* 0.93 
(0.92 – 0.94; 0.009) 
0.94 
(0.93 – 0.95; 0.008) 
0.118 0.94 
(0.93 – 0.95; 0.008) 
0.157 0.94 
(0.93 – 0.95; 0.008) 
0.118 0.94 
(0.93 – 0.95; 0.008) 
0.118 
 0h + 1h‡ 0.95 
(0.94 – 0.96; 0.009) 
0.96 
(0.95 – 0.97; 0.007) 
0.006 0.96 
(0.95 – 0.97; 0.008) 
0.007 0.96 
(0.95 – 0.97; 0.007) 
0.006 0.96 
(0.95 – 0.97; 0.007) 
0.006 
 0h + 0h/1h-delta‡ 0.94 
(0.93 – 0.95; 0.009) 
0.95 
(0.94 – 0.96; 0.009) 
0.014 0.95 
(0.94 – 0.96; 0.009) 
0.021 0.95 
(0.94 – 0.96; 0.009) 
0.014 0.95 
(0.94 – 0.96; 0.009) 
0.014 
*2225 patients, †1786 patients, ‡1752 patients 
 
 
Supplementary Table 8. IDI for events and non-events in the APACE cohort 
  combination p-value sum p-value Product p-value ratio p-value 
hs-cTnT IDI event     
IDI non event 
0.013 
-0.003 
< 0.001 -0.131 
0.028 
1.0 -0.244 
0.053 
1.0 -0.230 
0.050 
1.00 
hs-cTnI IDI event 
IDI non event 
0.174 
-0.038 
<0.001 0.031 
-0.007 
<0.001 -0.082 
0.018 
1.00 -0.068 
0.015 
1.00 
dedicates hs-cTnT resp. hs-cTnI alone (old model) versus combinations of hs-cTnT and hs-cTnI (new model) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 9. Comparison of the combination of signals from Abbott hs-cTnI and 
different (hs) cTnI assays at presentation 
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Abbott hs-cTnI and …  AUC: 0.93 
(0.92 – 0.94) 
AUC: 0.91 
(0.90 – 0.92) 
AUC: 0.92 
(0.90 – 0.94) 
AUC: 0.92 
(0.90 – 0.93) 
AUC: 0.94 
(0.93 – 0.95) 
Siemens c-TnI Ultra (n=2127) AUC: 0.89 
(0.88 – 0.90) 
P < 0.001 P = 0.006   P < 0.001 
Beckman hs-cTnI (n=1028) AUC: 0.93 
(0.91 – 0.94) 
P = 0.635  P = 0.119  P = 0.570 
Siemens hs-cTnI Vista (n=1348) AUC: 0.91 
(0.90 – 0.93) 
P = 0.073   P = 0.066 P = 0.057 
AUC (and the corresponding 95% confidence intervals), the comparison between AUCs was performed as 
recommended by Hanley and McNeil 
 
Supplementary Table 10. Comparison of the sum of the signals from Abbott hs-cTnTI and different 
(hs) cTnI assays at presentation 
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Abbott hs-cTnI and …  AUC: 0.93 
(0.92 – 0.94) 
AUC:0.91 
(0.90 – 0.92) 
AUC: 0.92 
(0.90 – 0.94) 
AUC: 0.92 
(0.90 – 0.93) 
AUC: 0.94 
(0.93 – 0.95) 
Siemens c-TnI Ultra (n=2127) AUC: 0.93 
(0.91 – 0.94) 
P = 0.286 P < 0.001   P = 0.021 
Beckman hs-cTnI (n=1028) AUC: 0.93 
(0.91 – 0.94) 
P = 0.715  P = 0.135  P = 0.143 
Siemens hs-cTnI Vista (n=1348) AUC: 0.93 
(0.91 – 0.94) 
P = 0.539   P = 0.013 P = 0.053 
AUC (and the corresponding 95% confidence intervals), the comparison between AUCs was performed as 
recommended by Hanley and McNeil 
 
 
 
 
 
Supplementary Table 11. Comparison of the product of the signals from Abbott hs-cTnI and 
different (hs) cTnI assays at presentation 
 
  A
b
b
o
tt
 h
s-
cT
n
I 
(n
=2
22
5)
 
Si
em
en
s 
c-
Tn
I U
lt
ra
 
(n
=2
12
7)
 
B
ec
km
an
 h
s-
cT
n
I 
(n
=1
02
8)
 
Si
em
en
s 
h
s-
cT
n
I V
is
ta
 
(n
=1
34
8)
 
P
ro
d
u
ct
 T
 a
n
d
 I 
Abbott hs-cTnI * …  AUC: 0.93 
(0.92 – 0.94) 
AUC:0.91 
(0.90 – 0.92) 
AUC: 0.92 
(0.90 – 0.94) 
AUC: 0.92 
(0.90 – 0.93) 
AUC: 0.94 
(0.93 – 0.95) 
Siemens c-TnI Ultra (n=2127) AUC: 0.93 
(0.92 – 0.94) 
P = 0.449 P < 0.001   P = 0.017 
Beckman hs-cTnI (n=1028) AUC: 0.93 
(0.91 – 0.95) 
P = 0.962  P = 0.030  P = 0.146 
Siemens hs-cTnI Vista 
(n=1348) 
AUC: 0.93 
(0.91 – 0.94) 
P = 0.560   P = 0.004 P = 0.031 
AUC (and the corresponding 95% confidence intervals), the comparison between AUCs was performed as 
recommended by Hanley and McNeil 
 
  
 
 
Supplementary Table 12. Descriptions of falsely ruled-out patients using the combination algorithm in the APACE cohort  
missed by 
 
 
age sex 
time since 
CPO, in h 
history of 
CAD 
0h hs-cTnT 
(ng/l) 
0h hs-cTnI 
(ng/l) 
ECG changes discharge diagnosis 
PCI 
performed 
PCI results 
combination 
algorithm 
75 1 1 yes 6.3 2.9 no stable angina no  
hs-cTnI <4ng/l 75 m 1 yes 6.3 2.9 no stable angina no  
 73 m 4 yes 33.3 3.4 no unclear no  
 74 f 1 no 10.0 3.1 no other cardiopathy yes LAD, LCX 
 93 f 9 yes 41.0 3.6 no unclear no  
 79 f 1 yes 18.0 3.9 ST-depression rhythm disorder no  
hs-cTnT <9ng/l 75 m 1 yes 6.3 2.9 no stable angina no   
 72 m 4 yes 8.0 7.5 RBBB NSTEMI yes  LAD, LCX, RCA 
 51 m 1 yes 7.1 27.9 no NSTEMI yes LAD, LCX, RCA 
 66 m 1 yes 4.8 6.4 no unclear yes LAD, LCX 
 57 f 0 yes 8.9 8.9 no unstable angina yes LAD, RCA 
 47 f 2 no 4.5 5.3 ST-depression  NSTEMI yes LAD 
 61 m 2 no 7.3 12.0 no unstable angina yes RCA 
 71 m 12 yes 8.8 4.5 no unstable angina yes LAD, LCX, Bypass 
 46 m 1 no 6.0 6.0 ST-depression  NSTEMI yes LCX 
 
 
 44 m 2 no 5.0 4.1 not sig. ST-elev. STEMI yes LCX, RCA 
 64 m 1 no 8.0 10.7 ST-depression STEMI yes  LCA, LCX 
 54 f  12 no 6.0 9.9  ST-depression  NSTEMI  yes  LCX 
 
Supplementary Table 13. Descriptions of falsely ruled-out patients in the ADAPT cohort 
missed by 
 
 
age sex 
time since 
CPO, in h 
history of 
CAD 
0h hs-cTnT 
(ng/l) 
0h hs-cTnI 
(ng/l) 
ECG changes discharge diagnosis 
PCI 
performed 
PCI results 
Sum 81 m 8 yes 6.5 2.1 no NSTEMI yes LAD, RCA 
 68 f 2 yes 0.1 2.4 no NSTEMI no  
 65 f 9 no 5.0 3.8 no NSTEMI no  
 60 m 1 no 0.1 0.1 yes STEMI yes LAD, LCX 
Product 81 m 8 yes 6.5 2.1 no NSTEMI yes LAD, RCA 
 60 m 1 no 0.1 0.1 yes STEMI yes LAD, LCX 
 68 f 2 yes 0.1 2.4 no NSTEMI no  
 59 m 2 yes 0.1 108.5 no NSTEMI no  
 54 m 9 yes 0.1 43.3 no NSTEMI yes No 
combination 
algorithm 
81 m 8 yes 6.5 2.1 no NSTEMI yes LAD, RCA 
 60 m 1 no 0.1 0.1 yes STEMI yes LAD, LCX 
 
 
 71 m 4 yes 7.8 4.6 no NSTEMI no  
 68 f 2 yes 0.1 2.4 no NSTEMI no  
 68 f 2 yes 0.1 2.4 no NSTEMI no  
hs-cTnI <4ng/l 81 m 8 yes 6.5 2.1 no NSTEMI yes LAD, RCA 
 60 m 1 no 0.1 0.1 yes STEMI yes LAD, LCX 
 71 m 4 yes 7.8 4.6 no NSTEMI no  
 68 f 2 yes 0.1 2.4 no NSTEMI no  
 65 f 9 no 5.0 3.8 no NSTEMI no  
hs-cTnT <9ng/l 81 M 7,73 yes 6.45 2.1 no NSTEMI yes LAD, RCA 
 40 M 9,68 yes 6.85 4.35 no NSTEMI yes LCA 
 79 F 2,65 no 6.67 5.5 yes STEMI no  
 60 M 0,97 no 0.1 0.1 yes NSTEMI yes LAD, LCX 
 59 M 2,33 yes 0.1 108.5 no NSTEMI no  
 42 M 21,43 no 8.41 22.7 no NSTEMI yes LCX, RCA 
 60 F 16,58 no 5.92 49.6 yes NSTEMI no  
 44 M 2,58 yes 6.93 41.85 no NSTEMI yes LCX, RCA 
 59 F 6,25 yes 7.6 28.5 no NSTEMI yes LCX, RCA 
 48 M 2,33 no 8.03 10 no NSTEMI yes LCX, RCA 
 71 M 3,53 yes 7.75 3.55 no NSTEMI no  
 58 F 0,60 no 7.39 10.2 yes NSTEMI yes n.a. 
 
 
 68 F 1,62 yes 0.1 2.4 no NSTEMI no  
 56 M 5,63 no 8.15 114.2 no NSTEMI yes n.a. 
 65 F 9,2 no 5.06 3.8 no NSTEMI no  
 54 M 9,0 yes 0.1 43.3 no NSTEMI yes n.a. 
  
 
 
Supplementary Figure 1. hs-cTn concentrations at presentation in the APACE cohort 
 
A) in hs-cTnT B) in hs-cTnI C) in the sum of hs-cTnT and hs-cTnI D) in the product of hs-cTnT and hs-cTnI 
E) in the ratio of hs-cTnT and hs-cTnI. The boxes represent median and inter-quartile ranges, the 
whiskers 1st-99th percentile. hs-cTn, high-sensitivity cardiac troponin; AMI, acute myocardial 
infarction; UA, unstable angina; CNC, cardiac non-coronary disease; NCCP, non-cardiac chest pain. 
 
